SCHEMBL3522495

SCHEMBL3522495

Cc1nc(=O)n(CC2CO2)c(=O)n1C

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.50
HBB P68871 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
DHFR P00374 1/20 0.35
GRIN1 Q05586 3/20 0.32
GRIN2B Q13224 3/20 0.32
HSD17B10 Q99714 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
CDK4 P11802 1/20 0.30
CCND1 P24385 1/20 0.30
CCND2 P30279 1/20 0.30
CCND3 P30281 1/20 0.30
PDE5A O76074 1/20 0.30
PDE4A P27815 1/20 0.30
PDE4B Q07343 1/20 0.30
PDE4C Q08493 1/20 0.30
PDE4D Q08499 1/20 0.30
TRPA1 O75762 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3518377 0.82 TP53 (0.53) TP53HBBSMN1; SMN2DHFRHSD17B10
SCHEMBL1715098 0.76 TP53 (0.78) TP53HBBSMN1; SMN2DHFRGRIN1
SCHEMBL22047578 0.76 TP53 (0.71) TP53HBBSMN1; SMN2DHFRGRIN1
SCHEMBL17804388 0.76 TP53 (0.78) TP53HBBSMN1; SMN2DHFRGRIN1
SCHEMBL10942045 0.76 TP53 (0.71) TP53HBBSMN1; SMN2DHFRGRIN1
SCHEMBL3525182 0.75 TP53 (0.47) TP53HBBSMN1; SMN2DHFR
SCHEMBL3525181 0.75 TP53 (0.47) TP53HBBSMN1; SMN2DHFR
SCHEMBL3524636 0.74 TP53 (0.55) TP53HBBSMN1; SMN2DHFRHSD17B10
SCHEMBL24779630 0.69 TP53 (0.59) TP53HBBSMN1; SMN2DHFR
SCHEMBL3521483 0.69 TNF (0.35) HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252810-B2 Bicycloamine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-08-28 US disclosed
US-8252810-B2 Bicycloamine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-08-28 US disclosed
US-8252810-B2 Bicycloamine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-08-28 US disclosed
US-20100331310-A1 BICYCLOAMINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-30 US disclosed
US-20100331310-A1 BICYCLOAMINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-30 US disclosed
US-20100331310-A1 BICYCLOAMINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-30 US disclosed
EP-2241567-A1 BICYCLOAMINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2010-10-20 EP disclosed
EP-2241567-A1 BICYCLOAMINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2010-10-20 EP disclosed
US-20090270369-A1 BICYCLOAMINE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-10-29 US disclosed
WO-2009101917-A1 BICYCLOAMINE DERIVATIVE EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331310-A1 BICYCLOAMINE DERIVATIVES SCN1B, KCNJ2, KCNH2 TP53 4878/4885HBB 3033/4885SMN1; SMN2 196/4885
US-20090270369-A1 BICYCLOAMINE DERIVATIVES SCN1B, KCNJ2, KCNH2 TP53 4878/4885HBB 3033/4885SMN1; SMN2 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.